Abraxis BioScience launches generic Adriamycin

Abraxis’ doxorubicin injection is the generic equivalent of Adriamycin PFS which is owned by Bedford Laboratories, a division of Boehringer Ingelheim.

According to IMS, sales in 2006 of doxorubicin hydrochloride injection in the US exceeded $30 million.

Contracts for this product have already been secured and Abraxis expects to immediately commence marketing of doxorubicin. The product is AP rated, preservative-free and latex-free.

Doxorubicin has been used to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of auxiliary lymph node involvement following resection of primary breast cancer.